Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of parathyroid hormones (1-34) in preparation of drugs for treating male hypogonadism

A technology for parathyroid hormone and hypofunction, which is applied in drug combinations, diseases, and pharmaceutical formulas, and can solve problems such as abnormal proliferation and differentiation, priapism, and ups and downs

Pending Publication Date: 2020-08-14
THE SECOND HOSPITAL AFFILIATED TO WENZHOU MEDICAL COLLEGE
View PDF5 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In these developmental processes, due to abnormal proliferation and differentiation, reduced quantity, and decreased function of hormone synthesis and secretion, it will also lead to androgen deficiency in the body.
[0004] At present, the clinical treatment of hypogonadism is mainly through testosterone supplementation therapy. However, in addition to the need for regular injections of testosterone, this therapy also has significant safety issues
Firstly, long-term quantitative supplementation of testosterone will make patients prone to acne and polycythemia; secondly, it will easily cause large fluctuations in serum testosterone concentration, which in turn will cause obvious fluctuations in the patient's mood and symptoms of delayed hypogonadism syndrome; thirdly, Patients are prone to adverse reactions such as water and sodium retention, priapism, and dysuria, and even liver and kidney function damage and prostate cancer and other diseases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of parathyroid hormones (1-34) in preparation of drugs for treating male hypogonadism
  • Application of parathyroid hormones (1-34) in preparation of drugs for treating male hypogonadism
  • Application of parathyroid hormones (1-34) in preparation of drugs for treating male hypogonadism

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0043] PTH 1-34 Differentiation-promoting effect on rat testicular mesenchymal stem cells

[0044] Male Sprague-Dawley rats (90 days old) were intraperitoneally injected with ethylenediaminetetraacetic acid (EDS, at a dose of 75 mg / kg body weight) 7 days before the experiment. After being killed by carbon dioxide, the testes were taken out and placed in ice-cold phosphate buffer In the process, the capsule was cut off, the blood vessels and seminiferous tubules were stripped, and the seminiferous tubules were separated into single ones, and the seminiferous tubules were evenly divided into 12-well plates, and placed in induction differentiation medium (DMEM / 12 medium from sigma company) , plus 5 mmol / L of lithium chloride and 5 ng / mL of LH) at 37° C. and cultured under the condition of 5% carbon dioxide for 2 weeks. In the second week, specific groups, different concentrations of PTH were added 1-34 Treatment of seminiferous tubules, specifically grouped as control group, 1,...

Embodiment 2

[0062] PTH 1-34 Therapeutic effect on EDS-treated hypotestosterone

[0063] Eighteen male Sprague-Dawley rats (90 days old). Intraperitoneal injection of 75mg / kg EDS to kill Leydig cells, divided into 3 groups (6 rats in each group): 1) blank (normal saline); 2) PTH 1-34 (1ng / testis / day); 3) PTH 1-34 (10ng / testis / day); daily intratesticular injections from day 7 of EDS to day 28 of EDS. Treat the animals, take blood and testes, use the method disclosed in Example 1 to analyze the testosterone content in the serum by chemiluminescence immunoassay, extract RNA from the Leydig cells and perform qPCR, and detect the mRNA levels of Star, Cyp11a1, Hsd3b1 and Hsd17b3, internal reference It is Rps16 (see Example 1 for details).

[0064] image 3 for PTH 1-34 Serum testosterone when stimulating the regeneration of mesenchymal stem cells; where, the data are represented by mean ± standard error, and the sample size is 6; "*" means P1-34 Increased serum testosterone production was ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an application of parathyroid hormones (1-34) in preparation of drugs for treating male hypogonadism, and belongs to the technical field of sexual function drugs. The PTH1-34 has the effects of improving the content of testosterone in the serums and testicles of organisms and promoting testicular mesenchymal stem cell differentiation of male organisms at the same time. Therefore, the PTH1-34 as active ingredients are applied to the preparation of the drugs for treating the male hypogonadism. The invention also provides a composition containing the parathyroid hormones (1-34) and parathyroid hormone related peptides and an application of the composition in preparation of drugs for treating the male hypogonadism, inducing the testicular mesenchymal stem cell differentiation or increasing the content of the testosterone in the testicles and serums.

Description

technical field [0001] The invention belongs to the technical field of sexual function drugs, in particular to the application of parathyroid hormone (1-34) in the preparation of drugs for treating male hypogonadism. Background technique [0002] "Improving the level of reproductive health and improving the quality of the birth population" is the theme of my country's mid- and long-term scientific and technological development plan, and it is also one of the core contents of my country's population health strategy. my country is a developing country with a large population, and the study of national reproductive health is a huge opportunity and challenge for our researchers engaged in reproductive biology and reproductive medicine. [0003] Male hypogonadism is a disease of hypogonadism caused by the lack or reduction of androgen or the inability to exert its function. Testosterone secreted by Leydig cells is the main source of androgen in males. Testosterone in human seru...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/29A61K38/18A61K38/24A61P15/08
CPCA61K38/29A61K38/24A61K38/185A61P15/08A61K2300/00
Inventor 王义炎葛仁山李晓珩李林溪朱琦琦李慧涛
Owner THE SECOND HOSPITAL AFFILIATED TO WENZHOU MEDICAL COLLEGE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com